Lilly files six lawsuits over retatrutide sold before approval
On August 12, 2026 Eli Lilly sued a med spa, a compounding pharmacy, and four online peptide sellers in California and Texas federal courts, and said it has referred more than 200 parties to regulators.
Published October 3, 2026 · Twenty Residues editorial
What the record establishes
- Lilly's release names six defendants: Aesthetic Envy Cosmetic Centers (N.D. Cal.), Astra LLC d/b/a Astra Peptides (W.D. Tex.), Legendary Peptides (E.D. Tex.), Striker Pharmacy (S.D. Tex.), Texas Peptides (W.D. Tex.), and Lone Star Peptide Co. (S.D. Tex.).
- Lilly states retatrutide is investigational, in Phase 3, and not approved for human use by any regulator anywhere.
- Lilly says it has referred more than 200 individuals and entities to FDA, DOJ, state attorneys general, law enforcement, and licensing boards, and reported more than 14,000 listings in over 100 countries to platforms and carriers.
- The release calls on payment processors, platforms, and shipping carriers to cut off sellers.
What it does not establish
- These are civil complaints filed by a company. No court has ruled. The release does not state the legal claims asserted (trademark, false advertising, or otherwise); the dockets do.
- Lilly's release does not allege that any defendant's product was tested and found to be something other than retatrutide. It argues the sale itself is unlawful.
- Nothing here addresses whether the product being sold is chemically the same as what is in Lilly's trials. That question is simply unanswered in the public record.
What would change this
A ruling on a motion to dismiss, a settlement, a default judgment, or any docket document characterizing the products' contents.
The open question
A drugmaker is suing to stop sales of a molecule it has not yet proven safe enough to sell itself. Who is that protecting, and does the answer change if the grey-market product turns out to be real retatrutide?
We don't answer this one. Take it to wherever you argue about peptides, and send us the strongest case from either side.
Propose a question by emailor on the public record
Sources
- [1]
- [2]
Related
FDA sends warning letters to five online peptide sellers in one day
Letters dated August 24, 2026 name NuScience Peptides, Royal Peptides, Peptide Partners, Peak Performance Peptides, and TXP Innovations. FDA says 'research use only' labels did not change its reading of intended use.
2 primary records · 1 secondary
Retatrutide Phase 3: 28.3% mean weight loss at 80 weeks, 11.3% quit the top dose
Lilly's May 21, 2026 topline release for TRIUMPH-1 reports all three doses met primary and key secondary endpoints. The same release reports discontinuation for adverse events rising with dose.
2 primary records · 0 secondary